10:07:16 Europe / Stockholm

Prenumeration

2021-02-03 11:30:00

Redeye has increased its estimates and valuation for Enea. We argue that it is time for the company to raise the bar in terms of the margin target of 20%, following having earned a 24% EBIT during the midst of a global pandemic. We also believe Enea can vastly surpass its 2023 sales target of SEK 1.5 bn (incl M&A), and the corresponding sales CAGR of 18%.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/